May. 20 at 5:18 PM
$BCTX is expanding beyond breast cancer — and ovarian could be the next big opportunity 👀
BriaCell is advancing Bria-OVA+, a next-gen personalized, off-the-shelf immunotherapy for ovarian cancer using its Bria-OTS+™ platform.
🧬 Management highlighted encouraging Phase 2 metastatic breast cancer data
🔥 Preclinical Bria-BRES+ data showed activation of T cells, dendritic cells, and NK cells
🎯 Development work for Bria-OVA+ is already underway after licensing ovarian cancer cell lines from ATCC
See what Wall Street expects next 👉
https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38152&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38152